INL1 | INNOLIFE

INL1 Development Strategy & Highlights

clincal-trials-details-2

Innolife discovered that at low concentrations, INL1 in fact serves as a copper redistribution shuttle to transport copper from high concentration gradient, e.g., the circulation, to copper depleted tissues such as ischemic or post-infarcted myocardial tissue, and then induces heart regeneration.

Ischemic Heart Failure 
New indications of INL1 under the US FDA 505(b)(2) NDA regulatory for Phase Ⅱ study.

1. Global multicenter clinical trial, Phase IIa
-Has completed PIND meeting with FDA
–505(b)(2) regulatory pathway
–Eligible for Fast Track, and possibly Breakthrough Therapy if achieved encouraging outcome in Ph IIa
-Indication Expandability: Besides Heart Failure as the main indication, FDA also agreed us to conduct additional phase II studies to explore two other indications: HFPEF and patients after ST-Elevated Myocardial Infarction.

2. CFDA new drug application
-Will start IND in China after completion of Ph IIa in the U.S.

3. Long Product Life Cycle
-Global patent filing, covering major PCT / non-PCT countries
-Comprehensive patent design, with 20 years protection period

Address:	Building10, Jingrong Center Zone A, Tianfu New Area, Chengdu, China 610000
Telephone:	+86-28-8670 7425
Cellphone:	+86-199 3429 5597
Email:	innolife@innolifehealth.com